Stockscreener 앱 받기
161.35
1.64%
2.61
시간 외 거래:
161.35
전일 마감가:
$158.74
열려 있는:
$160.44
하루 거래량:
1.10M
Relative Volume:
1.33
시가총액:
$7.94B
수익:
$4.02B
순이익/손실:
$-79.62M
주가수익비율:
-103.76
EPS:
-1.5551
순현금흐름:
$543.67M
1주 성능:
-14.72%
1개월 성능:
-26.32%
6개월 성능:
+4.10%
1년 성능:
+5.34%
1일 변동 폭
$156.58
$163.32
1주일 범위
$148.34
$188.70
52주 변동 폭
$91.86
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
161.35 | 7.81B | 4.02B | -79.62M | 543.67M | -1.5551 |
|
TMO
Thermo Fisher Scientific Inc
|
504.82 | 191.54B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
212.58 | 151.94B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
629.35 | 49.28B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
125.81 | 35.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
323.37 | 31.37B | 3.17B | 642.63M | 539.81M | 10.77 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-17 | 업그레이드 | Argus | Hold → Buy |
| 2025-11-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Charles River Laboratories International, Inc. $CRL Shares Bought by LSV Asset Management - MarketBeat
12 Best Mid Cap AI Stocks to Buy According to Hedge Funds - Insider Monkey
Commit To Purchase Charles River Laboratories International At $150, Earn 18.8% Annualized Using Options - Nasdaq
Here's How Charles River Stock Is Placed Ahead of Q4 Earnings - Yahoo Finance
Charles River Labs Quarterly Resilience Faces Declining Organic Revenue Test - simplywall.st
Halper Sadeh LLC Encourages Charles River Laboratories - GlobeNewswire
Madison Asset Management LLC Purchases Shares of 12,366 Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International Inc (CRL) Trading Down 8.73% on Feb 11 - GuruFocus
How Does Charles River Laboratories International Stock Compare With Peers? - Trefis
Synthace collaborates with Charles River to offer the global pharma industry more robust, faster and cost-effective assays - MSN
With Charles River Laboratories International Stock Sliding, Have You Assessed The Risk? - Trefis
Earnings Beat: Will Charles River Laboratories International Inc benefit from green energy policiesCEO Change & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Bank Watch: What is the next catalyst for Charles River Laboratories International Inc.Trade Entry Report & Technical Analysis for Trade Confirmation - mfd.ru
Versor Investments LP Invests $921,000 in Charles River Laboratories International, Inc. $CRL - MarketBeat
Thrivent Financial for Lutherans Has $2.31 Million Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International (CRL) to Release Earnings on Wednesday - MarketBeat
Assessing Charles River Laboratories (CRL) Valuation After Recent Share Price Pullback - simplywall.st
Charles River Labs (CRL) Shares Decline Following Industry Peer Earnings Report - GuruFocus
Principal Financial Group Inc. Grows Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
1 S&P 500 Stock with Competitive Advantages and 2 We Ignore - Finviz
Charles River and Synthace announce partnership for assay development - Drug Target Review
Charles River Laboratories International Insiders Up US$184k On US$1.25m Investment - 富途牛牛
Synthace & Charles River collaborate for robust, fast and cost-effective assays - SelectScience
Charles River Laboratories (CRL): Buy, Sell, or Hold Post Q3 Earnings? - Yahoo Finance
Canada Post Corp Registered Pension Plan Grows Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Is Charles River Laboratories stock underperforming the Dow? - MSN
Charles River Laboratories International (NYSE:CRL) Upgraded at Wall Street Zen - MarketBeat
Charles River shutters Maryland facility as activist investor pushes changes - The Business Journals
Oversold Conditions For Charles River Laboratories International (CRL) - Nasdaq
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Pharmaceutical giant to close 20,000-square-foot facility, lay off 20 - The Business Journals
Charles River Laboratories International Inc (CRL) Shares Down 6 - GuruFocus
Charles River Laboratories to Close Maryland Cell Therapy Site, Cut 20 Jobs - Contract Pharma
Zacks Research Has Positive Outlook for CRL Q4 Earnings - MarketBeat
Charles River Laboratories International, Inc. $CRL Position Boosted by Van Berkom & Associates Inc. - MarketBeat
[Latest] Global Adeno Associated Virus Vector Manufacturing Market Size/Share Worth USD 9.87 Billion by 2035 at a 13.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Shorts Report: Is Charles River Laboratories International Inc stock risky to hold nowJuly 2025 Highlights & Low Risk High Reward Ideas - baoquankhu1.vn
Bioburden Testing Market Generated Opportunities, Future - openPR.com
January M&A deals: Charles River Labs, Boston Scientific and ClearGov. - The Business Journals
Y Intercept Hong Kong Ltd Invests $1.18 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat
RSI Check: What is the Moat Score of Charles River Laboratories International IncQuarterly Market Summary & Fast Gaining Stock Reports - baoquankhu1.vn
What Charles River Laboratories International (CRL)'s Royalty-Free AAV Plasmid Tie-Up Means For Shareholders - simplywall.st
A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Momentum - Yahoo Finance
Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International, Inc. $CRL Shares Acquired by Cooke & Bieler LP - MarketBeat
What is the Moat Score of Charles River Laboratories International Inc.2025 AllTime Highs & Verified Stock Trade Ideas - mfd.ru
Charles River Labs Reshapes Gene Therapy Role While Legal Risks Linger - Sahm
Charles River Laboratories International (NYSE:CRL) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
1.13%
자본화:
|
볼륨(24시간):